BlackRock
ENZ

BlackRock’s Enzo Biochem, Inc. ENZ Stock Holding History

BlackRock’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-957,775
Closed -$354K – 5643
2025
Q1 		$354K Sell
957,775
-2,064
-0.2% -$1.14K ﹤0.01% 4478
2024
Q4 		$686K Buy
959,839
+688
+0.1% +$713 ﹤0.01% 4333
2024
Q3 		$1.07M Buy
959,151
+4,128
+0.4% +$4.62K ﹤0.01% 4159
2024
Q2 		$1.04M Buy
955,023
+1,032
+0.1% +$1.16K ﹤0.01% 4167
2024
Q1 		$1.21M Buy
953,991
+324
+0% +$428 ﹤0.01% 4148
2023
Q4 		$1.33M Sell
953,667
-1,727
-0.2% -$2.29K ﹤0.01% 4172
2023
Q3 		$1.34M Sell
955,394
-43,085
-4% -$65K ﹤0.01% 4149
2023
Q2 		$1.84M Sell
998,479
-421,909
-30% -$977K ﹤0.01% 4083
2023
Q1 		$3.45M Sell
1,420,388
-5,419
-0.4% -$8.06K ﹤0.01% 3803
2022
Q4 		$2.04M Sell
1,425,807
-42,314
-3% -$82.5K ﹤0.01% 4123
2022
Q3 		$3.27M Sell
1,468,121
-62,134
-4% -$150K ﹤0.01% 3941
2022
Q2 		$3.17M Sell
1,530,255
-10,336
-0.7% -$25.6K ﹤0.01% 4027
2022
Q1 		$4.47M Buy
1,540,591
+7,420
+0.5% +$23.8K ﹤0.01% 4030
2021
Q4 		$4.92M Buy
1,533,171
+1,001
+0.1% +$3.42K ﹤0.01% 4003
2021
Q3 		$5.42M Sell
1,532,170
-18,215
-1% -$60.8K ﹤0.01% 3927
2021
Q2 		$4.92M Sell
1,550,385
-2,357,869
-60% -$7.42M ﹤0.01% 3885
2021
Q1 		$13.4M Buy
3,908,254
+153,238
+4% +$477K ﹤0.01% 3413
2020
Q4 		$9.46M Buy
3,755,016
+146,250
+4% +$318K ﹤0.01% 3391
2020
Q3 		$7.62M Buy
3,608,766
+53,263
+1% +$127K ﹤0.01% 3381
2020
Q2 		$7.96M Sell
3,555,503
-93,709
-3% -$241K ﹤0.01% 3311
2020
Q1 		$9.23M Sell
3,649,212
-49,400
-1% -$121K ﹤0.01% 3042
2019
Q4 		$9.73M Buy
3,698,612
+11,347
+0.3% +$33.9K ﹤0.01% 3258
2019
Q3 		$13.3M Sell
3,687,265
-4,169
-0.1% -$14.8K ﹤0.01% 3054
2019
Q2 		$12.4M Sell
3,691,434
-227,680
-6% -$802K ﹤0.01% 3123
2019
Q1 		$10.7M Sell
3,919,114
-91,165
-2% -$298K ﹤0.01% 3085
2018
Q4 		$11.1M Buy
4,010,279
+17,405
+0.4% +$57K ﹤0.01% 3022
2018
Q3 		$16.5M Sell
3,992,874
-786
-0% -$3.57K ﹤0.01% 2976
2018
Q2 		$20.7M Buy
3,993,660
+313,826
+9% +$1.91M ﹤0.01% 2836
2018
Q1 		$20.2M Buy
3,679,834
+32,919
+0.9% +$232K ﹤0.01% 2771
2017
Q4 		$29.7M Sell
3,646,915
-72,606
-2% -$693K ﹤0.01% 2576
2017
Q3 		$38.9M Buy
3,719,521
+143,789
+4% +$1.6M ﹤0.01% 2435
2017
Q2 		$39.5M Buy
3,575,732
+384,184
+12% +$3.58M ﹤0.01% 2397
2017
Q1 		$26.7M Buy
3,191,548
+3,180,750
+29,457% +$22.4M ﹤0.01% 2586
2016
Q4 		$75K Hold
10,798
– – ﹤0.01% 2732
2016
Q3 		$55K Buy
10,798
+497
+5% +$2.97K ﹤0.01% 2921
2016
Q2 		$61K Buy
+10,301
New +$57.2K ﹤0.01% 2839
2014
Q2 		– Sell
-52
Closed – – 3232
2014
Q1 		$0 Buy
+52
New +$178 ﹤0.01% 3174

Other funds holding ENZ

RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

BlackRock's ENZ Position: Q2 2025 in Review

BlackRock sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 957,775 shares — an estimated $354K sold.

BlackRock first reported a position in ENZ in Q1 2014 and held it in 37 quarters. The position peaked at $39.5M in Q2 2017. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

  • BlackRock reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
  • BlackRock sold 957,775 Enzo Biochem, Inc. shares in Q2 2025, an estimated $354K.
  • BlackRock first reported a position in Enzo Biochem, Inc. in Q1 2014 and held it in 37 quarters.
  • BlackRock's Enzo Biochem, Inc. position peaked at $39.5M in Q2 2017.
  • 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.